Core Viewpoint - BioHarvest Sciences Inc. plans to conduct an underwritten public offering of its common stock, with a potential additional 15% of shares available for purchase by the underwriter [1][2]. Group 1: Offering Details - The offering is subject to market conditions and there is no assurance regarding its completion or the final terms [1]. - Craig-Hallum is the sole managing underwriter for the offering [2]. - A preliminary prospectus supplement will be filed with the SEC, detailing the terms of the proposed offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for various purposes, including research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes [2]. Group 3: Company Overview - BioHarvest is a leader in Botanical Synthesis, utilizing its patented technology to produce plant-based compounds without the need to grow the plants [5]. - The company operates in two main business verticals: as a contract development and production organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5].
BioHarvest Announces Proposed Public Offering of Common Stock